Immune Cell Subsets in SLE Patients Treated with Telitacicept

This study is a single-center cohort study. Patients with SLE who met the inclusion criteria were treated with tetanercept 160 mg once a week for a total of 24 weeks, and the clinical and laboratory indicators were collected before treatment, at the 4th week, at the 12th week, and at the 24th week, and blood samples were collected for the detection of immune cell subsets.

NCT Number	NCT06677801
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions	Systemic Lupus Erythematosus (SLE)
Enrollment	50 participants
Start Date	2024-10-11
Primary Completion	2026-10-31 (estimated)
Study Completion	2027-10-31 (estimated)
Updated on ClinicalTrials.gov	2024-11-07